Lu, Yen-Shen http://orcid.org/0000-0001-7461-1291
Yeo, Winnie
Yap, Yoon-Sim
Park, Yeon Hee
Tamura, Kenji
Li, Huiping
Cheng, Rebecca
Funding for this research was provided by:
Eli Lilly and Company
Article History
Accepted: 21 August 2021
First Online: 28 September 2021
Declarations
:
: Funding for this article was provided by Eli Lilly and Company.
: Yen-Shen Lu reports grants and personal fees from Novartis, Pfizer, Roche, and Merck Sharp and Dohme. Winnie Yeo reports personal fees from advisory and speaker roles from Novartis, Eli Lilly and Company, AstraZeneca, Pfizer, Merck, and Eisai. Yoon-Sim Yap reports personal fees and non-financial support from Roche, Eli Lilly and Company, Novartis, AstraZeneca, Pfizer, and Eisai. Yeon Hee Park reports grants and non-financial support from Pfizer, AstraZeneca, Novartis, Merck, Roche, and grants from Eisai. Rebecca Cheng reports personal fees from Eli Lilly and Company. Kenji Tamura and Huiping Li indicated no financial relationships.
: Not applicable.
: Not applicable.
: Y-SL, RC, and HL contributed to the conception of the manuscript. Y-SL, Y-SY, RC, and HL contributed to the study design. Y-SL, HL, RC, and YHP contributed to data acquisition. Y-SL, WY, Y-SY, KT, RC, YHP, and HL contributed to data interpretation. RC, and KT drafted the manuscript. Y-SL, WY, Y-SY, KT, HL, RC, and YHP critically reviewed the manuscript. All authors approved the final submitted version.
: Not applicable.
: Not applicable.
: Not applicable.